Quarterly report [Sections 13 or 15(d)]

Sponsored Research and License Agreements (Details)

v3.26.1
Sponsored Research and License Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 31 Months Ended
Jan. 31, 2024
Dec. 31, 2023
Apr. 30, 2021
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Dec. 31, 2025
Collaborations                  
Upfront payment received     $ 125,000,000.0            
Revenue recognized       $ 78,703,000 $ 101,685,000 $ 137,521,000 $ 155,018,000    
ocadusertib                  
Collaborations                  
Company's percentage of development costs           20.00%      
Revenue recognized         40,000,000.0        
Grifols                  
Collaborations                  
Deferred revenue       0   $ 0   $ 0 $ 0
Grifols | Royalty                  
Collaborations                  
Revenue recognized       2,000,000.0 1,600,000 3,700,000 3,100,000    
Kissei                  
Collaborations                  
Deferred revenue       0   0   0 0
Revenue recognized       1,600,000 400,000 3,400,000 2,000,000.0    
Kissei | fostamatinib                  
Collaborations                  
Deferred revenue       1,400,000 3,000,000.0 1,400,000 3,000,000.0 1,400,000 1,400,000
Revenue recognized       4,200,000   4,200,000      
Sublicensing fee payable       1,000,000.0   1,000,000.0      
Medison | fostamatinib                  
Collaborations                  
Revenue recognized       300,000 200,000 500,000 600,000    
Deferred revenue       0   0   0 $ 0
Non-Central Nervous System, Specified Development And Regulatory Milestone                  
Collaborations                  
Contingent payments           330,000,000.0      
Product-by-product Sales Milestone                  
Collaborations                  
Contingent payments           100,000,000.0      
Central Nervous System, Specified Development And Regulatory Milestone                  
Collaborations                  
Contingent payments           256,000,000.0      
Central Nervous System, Product-by-product Sales Milestone                  
Collaborations                  
Contingent payments           150,000,000.0      
Delivery of drug supply for commercialization | Grifols                  
Collaborations                  
Revenue recognized       $ 3,000,000.0 $ 400,000 3,000,000.0 $ 3,700,000    
Collaborative Arrangement                  
Collaborations                  
Contingent payments           652,100,000      
Collaborative Arrangement | Specified Development Events                  
Collaborations                  
Contingent payments           190,100,000      
Collaborative Arrangement | Specified Product Launch Events                  
Collaborations                  
Contingent payments           $ 462,000,000.0      
Strategic collaboration agreement with MDACC | REZLIDHIA                  
Collaborations                  
Amount due to collaboration partner   $ 15,000,000.0              
Collaboration period   5 years              
Payment of cost share to collaboration partner               $ 5,300,000  
Strategic collaboration agreement with Mdacc, clinical study enrollment support | REZLIDHIA                  
Collaborations                  
Amount due to collaboration partner   $ 1,000,000.0              
Strategic collaboration agreement with CONNECT | REZLIDHIA                  
Collaborations                  
Amount due to collaboration partner $ 3,000,000.0                
Collaboration period 4 years